Contact:                                                              For Media:

Chuck Soponis                                                      Joan Kureczka
Chief Executive Officer                               Kureczka/Martin Associates
Oragenics, Inc.                                                   (415) 821-2413
(386) 418-4018                                             Jkureczka@comcast.net

FOR IMMEDIATE RELEASE

                  ORAGENICS ANNOUNCES SUCCESSFUL MANUFACTURING
                               OF NOVEL ANTIBIOTIC

           Company Advances Mutacin 1140 into Preclinical Development

ALACHUA, FL (April 4, 2005): Oragenics, Inc. (AMEX:ONI) today announced that the
company has developed a proprietary manufacturing process for its novel
antibiotic drug candidate, Mutacin 1140, which overcomes a previous hurdle to
that molecule's development. The company said that it can now manufacture
Mutacin 1140 in sufficient quantities to enable Oragenics to conduct preclinical
studies needed to enable the filing of an Investigational New Drug (IND)
application for that compound. Mutacin 1140 is a novel peptide antibiotic.

Chuck Soponis, Oragenics chief executive officer commented, "Previously this
peptide has been difficult to produce in sufficient quantities to permit its
preclinical and clinical development --either synthetically, because of its
complex chemical structure or through standard fermentation methods. Now we have
solved this production challenge and can move forward with the necessary
preclinical studies over the next 15 to 18 months to support the filing of an
IND for Mutacin 1140."

About Oragenics

Oragenics, Inc. is an early stage biotechnology company focused on the
development and licensure of innovative products and technologies for improving
human health. The company's lead product is a novel oral rinse for the
prevention of tooth decay, which is anticipated to enter clinical trials in
2005. The company is also developing a novel antibiotic with broad-spectrum
activity against gram-positive bacteria and a probiotic product aimed at
maintaining oral health. The company is headquartered in Alachua, Florida. For
more information about Oragenics, please consult the company's website at
www.oragenics.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements which reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe", "expect", "anticipate",
"intend", "estimate", "project" and similar expressions that do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are


subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to (1)
the ability to successfully complete development and commercialization of
Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic,
and probiotic product for oral health; (2) the ability to produce Mutacin 1140
in commercial quantities; (3) the ability to obtain substantial additional
funding; (4) the ability to develop and commercialize products before our
competitors do; (5) the ability to develop commercial products with the
in-licensed technology; and (6) other factors detailed from time to time in
filings with the Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking statements.

                                      # # #